European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union

Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr

Arco Lab now holds a 50% stake in Neviton

Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore

Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties

Cipla EU to form JV in USA

Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases

Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

Servier and Base4 partner to advance neuroscience drug development

Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases

Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024

The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology